Why the study?
Does TA-6366 reduce blood pressure and inhibit ACE in preclinical models compared to captopril and enalapril?
Does TA-6366 reduce blood pressure and inhibit ACE in preclinical models compared to captopril and enalapril?
TA-6366 is a potent, long-lasting ACE inhibitor with antihypertensive efficacy in preclinical models comparable to enalapril and superior to captopril.
No takes yet. Share an insight, caveat, or question.
Supports TA-6366 advancement in models; leaves open human efficacy and safety.
Kubo et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: